secwatch.observer — SEC 8-K summary
======================================

Issuer:     GERON CORP (GERN)
CIK:        0000886744
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0000886744-25-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Geron Q1: RYTELO revenue $39.4M; demand flat; EU approval granted for LR-MDS
----------------------------------------------------------------------------

- RYTELO net product revenue $39.4M in Q1 2025; demand up only 1% vs prior 13 weeks due to inventory drawdown.
- European Commission granted marketing authorization for RYTELO; launch in select EU countries planned for 2026.
- Phase 3 IMpactMF trial for R/R myelofibrosis ~85% enrolled; interim OS analysis expected 2H 2026.
- Net loss improved to $19.8M ($0.03/share) vs $55.4M ($0.09/share) in Q1 2024 on first product revenue.
- FY2025 total operating expense guidance maintained at $270M-$285M; cash $457.5M as of March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/0000886744-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886744/000088674425000007/gern-20250507.htm
  HTML page:      https://secwatch.observer/filing/0000886744-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer